Former company will validate genes provided by the latter to determine functional relevance.
Alethia Biotherapeutics and Emerillon Therapeutics signed a collaborative research agreement to work together on bone-related diseases such as osteoporosis. The companies will conduct a discovery and functional validation program to identify new drug candidates.
According to the deal, Emerillon will provide a list of genetic loci that are associated with an osteoporotic phenotype in mice. In return, Alethia will generate bone-specific cDNA libraries to help identify these genes. It also will conduct cell-based validation studies to determine the functional relevance of the genes provided.